Rights and permissions
About this article
Cite this article
Patients with CML who achieve cytogenetic responses should receive imatinib mesylate. Inpharma Wkly. 1402, 15 (2003). https://doi.org/10.2165/00128413-200314020-00031
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200314020-00031